Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Trial Title: Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

NCT ID: NCT05738057

Condition: Unresectable Intrahepatic Cholangiocarcinoma

Conditions: Official terms:
Cholangiocarcinoma
Cisplatin
Gemcitabine

Study type: Interventional

Study phase: Phase 2

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Camrelizumab
Description: 200mg on day1 of every 3 weeks, starting on day1 of cycle1
Arm group label: Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and Camrelizumab

Intervention type: Drug
Intervention name: Gemcitabine Injection
Description: 1000mg/m2 on day1 & day8 of every 3 weeks, starting on day1 of cycle 1
Arm group label: Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and Camrelizumab

Intervention type: Drug
Intervention name: Cisplatin injection
Description: 25mg/m2 on day1 & day8 of every 3 weeks, starting on day1 of cycle 1
Arm group label: Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and Camrelizumab

Intervention type: Drug
Intervention name: Cisplatin-Eluting Beads
Description: used for D-TACE
Arm group label: Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and Camrelizumab

Intervention type: Procedure
Intervention name: D-TACE
Description: TACE with Cisplatin-Eluting Beads (with Cis 30mg). More TACE can be done if clinically necessary.
Arm group label: Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and Camrelizumab

Summary: The goal of this clinical trial is to learn about the combined therapy using drug-eluting bead-transarterial chemoembolization (D-TACE), gemcitabine (Gem) and cisplatin (Cis) chemotherapy, and PD-1 antibody in patients with advanced and unresectable intrahepatic cholangiocarcinoma (ICC). The main questions it aims to answer are: - Whether combined therapy using D-TACE, Gem/Cis, and PD-1 works well to convert unresectable ICC to resectable. - Whether combined therapy using D-TACE, Gem/Cis, and PD-1 is safe. Participants will receive D-TACE (CalliSpheres with Gem 30 mg), camrelizumab (200 mg) plus gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2), and 24 months follow-up.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Age ≥ 18 years old, male or female; 2. Histopathologically confirmed intrahepatic cholangiocarcinoma; 3. Tumor is unresectable assessed by the expert group (R0 resection CANNOT be achieved) and the life expectancy is more than 3 months; 4. Presence of at least one measurable lesion assessed using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST version 1.1); 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Child-Pugh score ≤ 7; 7. Adequate organ function (neutrophil count of ≥1.5×10^9 cells/L, hemoglobin concentrations of ≥90 g/L, platelet cell count of ≥100×10^9 cells/L, bilirubin ≤1.5×ULN, Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 5×ULN, serum creatinine ≤ 1.5 x ULN, Thyroid stimulating hormone (TSH) ≤ 1 x ULN; 8. The patient must be required to sign an informed consent form; Exclusion Criteria: 1. Patients who have received previous treatment with interventional therapy, radiotherapy, ablation, chemotherapy, targeted therapy, immunotherapy (PD-1, PD-L1, CLTA-4 antibody, etc), or surgery within the last 2 months; 2. Patients with other malignant tumors within the last 5 years, except for cured non-melanoma skin cancer, cervical carcinoma in situ, and papillary thyroid carcinoma; 3. Active tuberculosis infection. Patients with active tuberculosis infection within 1 year prior to enrollment; had a history of active tuberculosis infection more than 1 year before enrollment, did not receive formal anti-tuberculosis treatment or tuberculosis is still active; 4. Active infection requiring systemic therapy; 5. Human immunodeficiency virus (HIV) positive; 6. Have an active, known, or suspected autoimmune disease. Subjects who require only hormone replacement therapy for hypothyroidism and skin diseases that do not require systemic therapy may be enrolled; 7. Suffering from high blood pressure, and can not be well controlled by antihypertensive drugs (systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg); 8. Abnormal blood coagulation (INR >1.5, or PT>ULN+4s, or APTT >1.5 x ULN), with a bleeding tendency or receiving thrombolytic or anticoagulant therapy; 9. Pregnant or lactating women; 10. Participated in other trials within the last 4 weeks; 11. Has a history of allergy to platinum; 12. Other factors that may influence the safety of the subject or the compliance of the test by the investigator. Serious illnesses (including mental illness), severe laboratory tests, or other family or social factors that require combined treatment.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: The Third Affiliated Hospital of Sun Yat-Sen University

Address:
City: Guangzhou
Country: China

Status: Recruiting

Start date: June 30, 2023

Completion date: March 1, 2026

Lead sponsor:
Agency: Hua Li
Agency class: Other

Source: Third Affiliated Hospital, Sun Yat-Sen University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05738057